Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Logistic Properties of the Americas stock logo
LPA
Logistic Properties of the Americas
$2.98
+1.7%
$3.28
$2.04
$7.56
$92.64M5.2816,677 shs2,787 shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$119.05
-1.4%
$116.55
$76.66
$125.14
$298.26B0.2110.16 million shs10.93 million shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$14.01
+7.1%
$18.55
$12.55
$30.98
$10.15B-1.325.90 million shs9.84 million shs
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$34.58
+0.0%
$33.28
$14.99
$37.35
$39.74B0.845.70 million shs5.93 million shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Logistic Properties of the Americas stock logo
LPA
Logistic Properties of the Americas
+2.81%+1.38%-18.16%+14.45%-60.51%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
+1.52%+0.48%+7.48%+4.49%+50.51%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
+0.23%-11.86%-30.98%-18.86%-33.20%
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
+3.01%+0.49%-3.52%+21.08%+99.72%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Logistic Properties of the Americas stock logo
LPA
Logistic Properties of the Americas
$2.98
+1.7%
$3.28
$2.04
$7.56
$92.64M5.2816,677 shs2,787 shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$119.05
-1.4%
$116.55
$76.66
$125.14
$298.26B0.2110.16 million shs10.93 million shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$14.01
+7.1%
$18.55
$12.55
$30.98
$10.15B-1.325.90 million shs9.84 million shs
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$34.58
+0.0%
$33.28
$14.99
$37.35
$39.74B0.845.70 million shs5.93 million shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Logistic Properties of the Americas stock logo
LPA
Logistic Properties of the Americas
+2.81%+1.38%-18.16%+14.45%-60.51%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
+1.52%+0.48%+7.48%+4.49%+50.51%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
+0.23%-11.86%-30.98%-18.86%-33.20%
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
+3.01%+0.49%-3.52%+21.08%+99.72%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Logistic Properties of the Americas stock logo
LPA
Logistic Properties of the Americas
2.00
Hold$7.50151.68% Upside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.68
Moderate Buy$128.187.66% Upside
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
2.47
Hold$27.2394.33% Upside
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
2.80
Moderate Buy$41.7820.83% Upside

Current Analyst Ratings Breakdown

Latest SMMT, MRK, LPA, and TEVA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/1/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Reiterated RatingOverweight
5/24/2026
Logistic Properties of the Americas stock logo
LPA
Logistic Properties of the Americas
Set Price Target$7.50
5/22/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Reiterated RatingOverweight
5/22/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
DowngradeBuyNeutral
5/21/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Initiated CoverageUnderperform$7.70
5/21/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
UpgradeStrong Sell
5/15/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
DowngradeHold (C+)Hold (C)
5/13/2026
Logistic Properties of the Americas stock logo
LPA
Logistic Properties of the Americas
UpgradeHold
5/6/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Initiated CoverageNeutral$125.00
5/6/2026
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
Boost Price TargetOverweight$38.00 ➝ $40.00
5/4/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Lower Price TargetBuy$30.00 ➝ $23.00
(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Logistic Properties of the Americas stock logo
LPA
Logistic Properties of the Americas
$50.13M1.88$0.37 per share8.05$10.27 per share0.29
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$65.01B4.52$11.26 per share10.57$21.22 per share5.61
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/A$0.85 per shareN/A
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$17.26B2.30$3.73 per share9.27$6.88 per share5.03
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Logistic Properties of the Americas stock logo
LPA
Logistic Properties of the Americas
$10.50MN/A29.803.59N/A6.31%1.08%0.49%8/12/2026 (Estimated)
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$18.25B$3.5533.5412.092.7213.59%27.55%10.73%8/4/2026 (Estimated)
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$1.08B-$1.60N/AN/AN/AN/A-291.24%-243.07%8/10/2026 (Estimated)
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$1.41B$1.3326.0011.373.539.01%43.53%8.19%7/29/2026 (Estimated)

Latest SMMT, MRK, LPA, and TEVA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2026Q1 2026
Logistic Properties of the Americas stock logo
LPA
Logistic Properties of the Americas
N/A-$0.25N/A-$0.25N/A$14.40 million
5/1/2026Q1 2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$0.2692-$0.24+$0.0292-$0.24$0.05 millionN/A
4/30/2026Q1 2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-$1.47-$1.28+$0.19-$1.72$15.85 billion$16.29 billion
4/29/2026Q1 2026
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$0.50$0.53+$0.03$0.31$3.79 billion$3.98 billion
3/31/2026Q1 2026
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
N/A$0.53N/A$0.31N/A$3.98 billion
3/18/2026Q4 2025
Logistic Properties of the Americas stock logo
LPA
Logistic Properties of the Americas
N/A$0.1950N/A$0.1950N/A$13.71 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Logistic Properties of the Americas stock logo
LPA
Logistic Properties of the Americas
N/AN/AN/AN/AN/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.402.86%+5.75%95.77%14 Years
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/AN/A
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
N/AN/AN/AN/AN/A

Latest SMMT, MRK, LPA, and TEVA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/26/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.852.84%6/15/20266/15/20267/8/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Logistic Properties of the Americas stock logo
LPA
Logistic Properties of the Americas
0.93
1.57
1.57
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
1.02
1.30
1.06
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/A
7.41
7.41
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
1.70
1.01
0.78
CompanyEmployeesShares OutstandingFree FloatOptionable
Logistic Properties of the Americas stock logo
LPA
Logistic Properties of the Americas
3031.62 million21.50 millionN/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
75,0002.47 billion2.47 billionOptionable
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
110776.16 million128.07 millionOptionable
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
33,9501.15 billion1.14 billionOptionable

Recent News About These Companies

Is Amneal a Buy Before Rytary Generic Erosion?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Logistic Properties of the Americas stock logo

Logistic Properties of the Americas NYSEAMERICAN:LPA

$2.98 +0.05 (+1.71%)
Closing price 04:10 PM Eastern
Extended Trading
$2.88 -0.10 (-3.49%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Logistic Properties of the Americas develops, builds and operates logistic real estate properties. It operates through the following geographical segments: Colombia, Peru, and Costa Rica. The company is headquartered in Miami, FL.

Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$119.05 -1.71 (-1.41%)
Closing price 03:59 PM Eastern
Extended Trading
$119.24 +0.19 (+0.16%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Summit Therapeutics stock logo

Summit Therapeutics NASDAQ:SMMT

$14.01 +0.93 (+7.11%)
Closing price 04:00 PM Eastern
Extended Trading
$14.15 +0.14 (+1.03%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Teva Pharmaceutical Industries stock logo

Teva Pharmaceutical Industries NYSE:TEVA

$34.58 +0.02 (+0.04%)
Closing price 03:59 PM Eastern
Extended Trading
$34.57 0.00 (0.00%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.